Tiziana Life Sciences

Yahoo Finance • 3 months ago

Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA

Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposureFDA denial of Sanofi’s tolebrutinib for nrSPMS shows need for safe therapy BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana... Full story

Yahoo Finance • 4 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal... Full story

Yahoo Finance • 4 months ago

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanemab) Anti-Amyloid Therapy BOSTON, Dec. 12, 2025 (GLOBE NEWSWIRE) -- T... Full story

Yahoo Finance • 4 months ago

Why Is Tiziana Life Stock Falling In Pre-market?

(RTTNews) - Tiziana Life Sciences (TLSA) announced that it intends to develop its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, and related assets via a spinout into a separate publicly traded company. The company said Tizi... Full story

Yahoo Finance • 4 months ago

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

Tiziana Life Sciences Ltd. BOSTON, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that... Full story

Yahoo Finance • 5 months ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical tria... Full story

Yahoo Finance • 5 months ago

3 Promising Penny Stocks With At Least $40M Market Cap

Major stock indexes in the United States have mostly risen, with investors eagerly anticipating Nvidia's earnings report, which could influence broader market trends. Though the term 'penny stock' might sound like a relic of past trading d... Full story

Yahoo Finance • 5 months ago

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal... Full story

Yahoo Finance • 7 months ago

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Tiziana Life Sciences Ltd. BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) mo... Full story

Yahoo Finance • 7 months ago

Tiziana Life Sciences Announces Purchase of Shares by Chairman

BOSTON, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasa... Full story

Yahoo Finance • 8 months ago

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

BOSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal... Full story

Yahoo Finance • 9 months ago

Tech Voices: OpenAI warns on stock tokens, CoreWeave-Nvidia, Apple

[Moscow, Russia - April 7, 2019: NVIDIA video chip on the motherboard] Antonio Bordunovi _Seeking Alpha's daily roundup of statements and remarks that could impact the technology sector._ * OpenAI and Elon Musk are advising investors th... Full story

Yahoo Finance • 10 months ago

Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranas... Full story

Yahoo Finance • 10 months ago

Tiziana shares rise on presentation date for foralumab data

[Laptop computer stand on wooden meeting table] BongkarnThanyakij/iStock via Getty Images * Tiziana Life Sciences (NASDAQ:TLSA [https://seekingalpha.com/symbol/TLSA]) shares rose on Friday after the company said that its CEO, Ivor Elrif... Full story

Yahoo Finance • 10 months ago

Tiziana Life Sciences to Present at the Bio International Convention

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranas... Full story

Yahoo Finance • 11 months ago

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasa... Full story

Yahoo Finance • last year

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intrana... Full story

Yahoo Finance • last year

Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intrana... Full story

Yahoo Finance • last year

Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranas... Full story

Yahoo Finance • last year

Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranas... Full story